Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature and RenaSci strengthen drug abuse leadership with appointment of Dr Andy Mead

Sygnature has appointed Dr Andy Mead as Director and Head of Drug Abuse and Substance Use Disorders at our integrated in vivo pharmacology company, RenaSci.

With 25 years’ experience in the science of drug abuse and addiction across academia, biotech and pharma (including NIDA, Merck, Pfizer and AstraZeneca), Dr Mead brings strategic and scientific leadership to a well-established team of drug abuse specialists, and will drive the development and expansion of our non-clinical drug abuse and substance use disorders capabilities.

For our customers, this senior appointment adds a rare depth of expertise around non-clinical assessment and regulatory strategy, with Dr Mead bringing extensive experience across a wide range of abuse liability assessments, and will ensure expert collaboration and consultancy in meeting the regulatory requirements for drug abuse assessment during the development of novel therapeutic agents.

Dr Mead’s specialist knowledge in safety pharmacology and discovery toxicology will also complement and add value to the expertise already on offer across a variety of therapeutic areas at Sygnature.

“I have always been passionate about the science of drug abuse and addiction,” said Dr Mead, “and there is so much need for it today – both ensuring patient safety through the assessment of abuse liability, as well as directly addressing patient need through discovering novel treatments for substance use disorders.

“This role gives me the exciting opportunity to collaborate across all sectors of the healthcare industry to pursue both of those aspects, building on RenaSci’s established reputation for scientific quality and collaboration, and aligned with Sygnature Discovery’s vision to deliver the best science through innovation and tailored integrated drug discovery and pre-clinical expertise.”

Dr Mead joins us from Sosei Heptares, where he was Director of Discovery and Translational Safety. His industry experience is backed by an internationally-recognised publication record for developing the science of drug abuse and substance use disorders, extensive regulatory experience in the area of abuse liability, as well as a strong track record for progressing molecules from concept through to clinical development across a range of therapeutic areas.

Dr Simon Hirst, Founder and CEO at Sygnature added, “The worldwide opioid crisis has brought the field of drug abuse liability and treatment to the forefront of science. But with the variety of models involved, it is an extremely complex undertaking. To advance new molecules to market, it is critical that both the quality of the science and the drug development strategy behind it are at the highest level.

“With a history of providing pre-clinical solutions in this challenging area, I am thrilled at the prospect of Andy joining to head-up a team of scientists with a world-renowned reputation. Andy’s experience will not only strengthen the expertise of this team, but as a well-respected and dynamic scientist he will ensure we remain at the fore-front of this exciting area.”

Latest News

View All

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.